Literature DB >> 10588919

Stereoselective central nervous system effects of the R- and S-isomers of the GABA uptake blocker N-(4, 4-di-(3-methylthien-2-yl)but-3-enyl) nipecotic acid in the rat.

A Cleton1, H J de Greef, P M Edelbroek, R A Voskuyl, M Danhof.   

Abstract

1. The 'effect compartment' model was applied to characterize the pharmacodynamics of the R- and S-isomers of tiagabine in conscious rats in vivo using increase in the beta activity of the EEG as a pharmacodynamic endpoint. 2. No pharmacokinetic differences in plasma were observed between R- and S-tiagabine. The values for clearance and volume of distribution at steady-state were 103+/-10 versus 90+/-6 ml min(-1) kg(-1) and 1.8+/-0.2 versus 1.6+/-0.2 l kg(-1) for the R- and S-isomer, respectively. In contrast, plasma protein binding showed a statistically significant difference with values of the free fraction of 5.7+/-0.5 and 11.4+/-0.6%. In addition the rate constant for transport to the effect compartment was also different with values of 0.027 versus 0.067 min(-1). 3. For both isomers the relationship between concentration and EEG effect was non-linear and successfully characterized on basis of the Hill equation. A statistically significant difference in the value of EC(50) of 328+/-11 versus 604+/-18 ng ml(-1) was observed for R- and S-tiagabine respectively. The values of the other pharmacodynamic parameters were identical. 4. It is concluded that the differences in in vivo pharmacodynamics of R- and S-tiagabine can be explained by stereoselective differences in both the affinity to the GABA-uptake transporter and the degree of non-specific protein binding in plasma and at the effect site.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10588919      PMCID: PMC1571804          DOI: 10.1038/sj.bjp.0702962

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  20 in total

Review 1.  Effect of chirality on pharmacokinetics and pharmacodynamics.

Authors:  W R Crom
Journal:  Am J Hosp Pharm       Date:  1992-09

2.  High-performance liquid chromatographic procedure for the determination of tiagabine concentrations in human plasma using electrochemical detection.

Authors:  L E Gustavson; S Y Chu
Journal:  J Chromatogr       Date:  1992-02-14

3.  Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of heptabarbital using aperiodic EEG analysis.

Authors:  J W Mandema; M Danhof
Journal:  J Pharmacokinet Biopharm       Date:  1990-10

4.  Semiparametric approach to pharmacokinetic-pharmacodynamic data.

Authors:  D Verotta; S L Beal; L B Sheiner
Journal:  Am J Physiol       Date:  1989-04

Review 5.  GABA synaptic mechanisms: stereochemical and conformational requirements.

Authors:  P Krogsgaard-Larsen
Journal:  Med Res Rev       Date:  1988 Jan-Mar       Impact factor: 12.944

6.  Application of a combined "effect compartment/indirect response model" to the central nervous system effects of tiagabine in the rat.

Authors:  A Cleton; H J de Greef; P M Edelbroek; R A Voskuyl; M Danhof
Journal:  J Pharmacokinet Biopharm       Date:  1999-06

7.  (R)-N-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]nipecotic acid binds with high affinity to the brain gamma-aminobutyric acid uptake carrier.

Authors:  C Braestrup; E B Nielsen; U Sonnewald; L J Knutsen; K E Andersen; J A Jansen; K Frederiksen; P H Andersen; A Mortensen; P D Suzdak
Journal:  J Neurochem       Date:  1990-02       Impact factor: 5.372

8.  Quantitative autoradiographic characterization of the binding of [3H]tiagabine (NNC 05-328) to the GABA uptake carrier.

Authors:  P D Suzdak; C Foged; K E Andersen
Journal:  Brain Res       Date:  1994-06-06       Impact factor: 3.252

9.  The synthesis of novel GABA uptake inhibitors. 1. Elucidation of the structure-activity studies leading to the choice of (R)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic acid (tiagabine) as an anticonvulsant drug candidate.

Authors:  K E Andersen; C Braestrup; F C Grønwald; A S Jørgensen; E B Nielsen; U Sonnewald; P O Sørensen; P D Suzdak; L J Knutsen
Journal:  J Med Chem       Date:  1993-06-11       Impact factor: 7.446

10.  Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor.

Authors:  E B Nielsen; P D Suzdak; K E Andersen; L J Knutsen; U Sonnewald; C Braestrup
Journal:  Eur J Pharmacol       Date:  1991-04-24       Impact factor: 4.432

View more
  1 in total

1.  Effect of amygdala kindling on the central nervous system effects of tiagabine: EEG effects versus brain GABA levels.

Authors:  A Cleton; B A Altorf; R A Voskuyl; M Danhof
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.